Micromet hits 52-week-high on experimental cancer drug results
Micromet Inc. (NASDAQ:MITI) hit a new 52-week-high this morning as the stock continued to benefit from positive data on one of its cancer drug candidates being published in Science magazine.
The Bethesda, Md., biopharmaceutical company says its experimental drug blinatumomab has produced promising early-stage results in patients with a fatal form of blood cancer...
For access to the full article, you must be a registered member - it's FREE.
Already a member? Please log in below
Not Registered?
Register today and enjoy all that SmallCapInvestor.com has to offer, including:
- Daily small cap stock profiles.
- Intra-day coverage of Russell 2000 companies.
- Research and insights from our analysts.
- Special reports.
